Company Overview of Canaccord Genuity Inc.

Canaccord Genuity announced that David V. Hedley III and Ben Gibson have joined the firm's growing technology practice in San Francisco as Managing Directors of Investment Banking. Both Mr. Hedley and Mr. Gibson will work on a broad range of technology assignments, including public offerings, private placements, and merger and acquisition advisory work. They will be responsible for Canaccord Genuity's west coast technology banking efforts, focusing primarily on all areas of the hardware sector including semiconductors, electronics and communications equipment. Mr. Hedley joins Canaccord Genuity from the UBS Global Technology Group where he was a Managing Director and head of the Hardware and Electronics Supply Chain team. Mr. Gibson is relocating to Canaccord Genuity's San Francisco office from the firm's Montreal office, where he has worked since 2000 and most recently held the role of Co-Head of Canadian Technology Investment Banking.

Canaccord Genuity Inc. took on Julian Feneley as head of healthcare investment banking, Europe. Based in London, he will report to Adrian Haxby, head of European investment banking. Feneley is a co-founder of Smile! Marketing LLC and Dose Skincare LLC . He was president and CEO of BriteSmile Inc. from January 2004 to January 2008, managing director and head of corporate finance at BioScience Managers from March 2001 to December 2003 and CEO of Narrowbridge from March 2000 to March 2001. Feneley also spent 10 years at JPMorgan Chase & Co., where he advised on the creation of Novartis AG, Pharmacia & Upjohn and AstraZeneca plc.

Canaccord Genuity Inc. Presents at 15th Annual Bio CEO & Investor Conference, Feb-11-2013 through Feb-12-2013. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States. Presentation Date & Speakers: Feb-12-2013, Ritu S. Baral, Principal, Sr. Analyst ­ Biotechnology Equity Research, Salveen Richter, Managing Director, Biotechnology Equity Research.